ArticleJournal of translational medicine2006
The thrombopoietin receptor, c-Mpl, is a selective surface marker for human hematopoietic stem cells.
Article in Journal of translational medicine, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed.
- Trial
- Cellular profile of hematopoietic stem cells mobilized by exercise versus G-CSF in healthy related donors.European journal of applied physiology · 2026Article
- C-MPL signaling in breast cancer: molecular mechanisms and therapeutic implications.Annals of medicine and surgery (2012) · 2026Article
- The Effect of Tumor Necrosis Factor-α and Interleu-Kin-1β on the Restorative Properties of Human Oligodendrocyte Precursor Cells In Vitro.Bioengineering (Basel, Switzerland) · 2025Article
- Cell Lineage Affiliation During Hematopoiesis.International journal of molecular sciences · 2025Review
- Recombinant human thrombopoietin improves hematopoietic stem cell differentiation and T-cell immune homeostasis in patients with severe aplastic anemia by upregulating c-MPL.Frontiers in pharmacology · 2025Article
- A review on the functional characteristics of the c-Myeloproliferative Leukaemia (c-MPL) gene and its isoforms.Cellular oncology (Dordrecht, Netherlands) · 2024Review
- Article
- Advances in ex vivo expansion of hematopoietic stem and progenitor cells for clinical applications.Frontiers in bioengineering and biotechnology · 2024Review
- Hematopoietic stem cells and extramedullary hematopoiesis in the lungs.Cytometry. Part A : the journal of the International Society for Analytical Cytology · 2023Review
- An NFIX-mediated regulatory network governs the balance of hematopoietic stem and progenitor cells during hematopoiesis.Blood advances · 2023Article
- Clinical Care Team's Guide for Awareness on Risk Assessment of Eltrombopag Complicating Acute Kidney Injury in Relapsed Immune Thrombocytopenic Patients: A Case Report.Medicina (Kaunas, Lithuania) · 2023Article
- Platelets at the Vessel Wall in Non-Thrombotic Disease.Circulation research · 2023Review
- Thrombopoietin-based CAR-T cells demonstrate in vitro and in vivo cytotoxicity to MPL positive acute myelogenous leukemia and hematopoietic stem cells.Gene therapy · 2022Article
- Exploring the Potential of Eltrombopag: Room for More?Frontiers in pharmacology · 2022Article
- Human hematopoietic microenvironments.PloS one · 2021Article
- On the Quest for In Vitro Platelet Production by Re-Tailoring the Concepts of Megakaryocyte Differentiation.Medicina (Kaunas, Lithuania) · 2020Review
- Modeling the Hematopoietic Landscape.Frontiers in cell and developmental biology · 2019Review
- The thrombopoietin mimetic romiplostim leads to the complete rescue of mice exposed to lethal ionizing radiation.Scientific reports · 2018Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundThrombopoietin (TPO), the primary cytokine regulating megakaryocyte proliferation and differentiation, exerts significant influence on other hematopoietic lineages as well, including erythroid, granulocytic and lymphoid lineages. We previously demonstrated that the receptor for TPO, c-mpl, is expressed by a subset of human adult bone marrow hematopoietic stem/progenitor cells (HSC/PC) that are enriched for long-term multilineage repopulating ability in the SCID-hu Bone in vivo model of human hematopoiesis.
methodsHere, we employ flow cytometry and an anti-c-mpl monoclonal antibody to comprehensively define the surface expression pattern of c-mpl in four differentiation stages of human CD34+ HSC/PC (I: CD34+38--, II: CD34+38dim, III: CD34+38+, IV: CD34dim38+) for the major sources of human HSC: fetal liver (FL), umbilical cord blood (UCB), adult bone marrow (ABM), and cytokine-mobilized peripheral blood stem cells (mPBSC). We use a surrogate in vivo model of human thymopoiesis, SCID-hu Thy/Liv, to compare the capacity of c-mpl+ vs. c-mpl-- CD34+38--/dim HSC/PC for thymocyte reconstitution.
resultsFor all tissue sources, the percentage of c-mpl+ cells was significantly highest in stage I HSC/PC (FL 72 +/- 10%, UCB 67 +/- 19%, ABM 82 +/- 16%, mPBSC 71 +/- 15%), and decreased significantly through stages II, III, and IV ((FL 3 +/- 3%, UCB 8 +/- 13%, ABM 0.6 +/- 0.6%, mPBSC 0.2 +/- 0.1%) [ANOVA: P < 0.0001]. The relative median fluorescence intensity of c-mpl expression was similarly highest in stage I, decreasing through stage IV [ANOVA: P < 0.0001]. No significant differences between tissue sources were observed for either % c-mpl+ cells [P = 0.89] or intensity of c-mpl expression [P = 0.21]. Primary Thy/Liv grafts injected with CD34+38--/dimc-mpl+ cells showed slightly higher levels of donor HLA+ thymocyte reconstitution vs. CD34+38--/dimc-mpl---injected grafts and non-injected controls (c-mpl+ vs. c-mpl--: CD2+ 6.8 +/- 4.5% vs. 2.8 +/- 3.3%, CD4+8-- 54 +/- 35% vs. 31 +/- 29%, CD4--8+ 29 +/- 19% vs. 18 +/- 14%).
conclusionThese findings support the hypothesis that the TPO receptor, c-mpl, participates in the regulation of primitive human HSC from mid-fetal through adult life. This study extends our previous work documenting human B-lineage, myeloid and CD34+ cell repopulation by c-mpl+ progenitors to show that c-mpl+ HSC/PC are also capable of significant T-lineage reconstitution in vivo. These results suggest that c-mpl merits consideration as a selective surface marker for the identification and isolation of human HSC in both basic research and clinical settings.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.